Latest Boehringer Ingelheim International GmbH Stories
- Retrospective analysis of more than 38,000 patients shows PRADAXA is associated with lower rates of stroke and major bleeding compared to warfarin RIDGEFIELD, Conn., Nov.
Findings presented at American Heart Association's Scientific Sessions add to growing body of data supporting safety and effectiveness of PRADAXA RIDGEFIELD, Conn., Nov.
- RE-VERSE AD(TM) is being conducted in more than 35 countries with aim to enroll 250 patients RIDGEFIELD, Conn., Nov. 10, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- Poster on research about investigational, specific antidote for PRADAXA also to be presented RIDGEFIELD, Conn., Nov. 10, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
Largest observational study of a newer oral anticoagulant, with more than 134,000 elderly patients, published in Circulation RIDGEFIELD, Conn., Nov. 3, 2014 /PRNewswire/ -- A U.S.
Patients at higher risk of kidney problems due to existing diabetes were also evaluated for the effects of warfarin on kidney function RIDGEFIELD, Conn., Sept.
Hot Line session presentations to feature renal function data from pivotal RE-LY® trial and global GLORIA(TM)-AF registry updates RIDGEFIELD, Conn., Aug.
British Medical Journal publishes biased article regarding PRADAXA RIDGEFIELD, Conn., July 23, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) wants to set the record straight following misleading
RIDGEFIELD, Conn., June 20, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today the initiation of a new international study of Pradaxa® (dabigatran etexilate mesylate).
Three pivotal trials showed PRADAXA as non-inferior to warfarin in reduction of DVT and PE recurrence; fourth pivotal trial showed PRADAXA reduced risk of recurrence by 92 percent compared to placebo RIDGEFIELD,
- To give a box on the ear to.